Broadly neutralizing antibodies and monoclonal V2 antibodies derived from RV305 inhibit capture and replication of HIV-1

Jiae Kim; Zuzana Villar; Ousman Jobe; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Robert J. O'Connell; Julie A. Ake; Sandhya Vasan; Venigalla B. Rao; Mangala Rao

doi:10.1016/j.virol.2024.110158

Broadly neutralizing antibodies and monoclonal V2 antibodies derived from RV305 inhibit capture and replication of HIV-1

Jiae Kim^*, Zuzana Villar, Ousman Jobe, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, Robert J. O'Connell, Julie A. Ake, Sandhya Vasan, Venigalla B. Rao, Mangala Rao^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

An important approach to stopping the AIDS epidemic is the development of a vaccine that elicits antibodies that block virus capture, the initial interactions of HIV-1 with the target cells, and replication. We utilized a previously developed qRT-PCR-based assay to examine the effects of broadly neutralizing antibodies (bNAbs), plasma from vaccine trials, and monoclonal antibodies (mAbs) on virus capture and replication. A panel of bNAbs inhibited primary HIV-1 replication in PBMCs but not virus capture. Plasma from RV144 and RV305 trial vaccinees demonstrated inhibition of virus capture with the HIV-1 subtype prevalent in Thailand. Several RV305 derived V2-specific mAbs inhibited virus replication. One of these RV305 derived V2-specific mAbs inhibited both virus capture and replication, demonstrating that it is possible to elicit antibodies by vaccination that inhibit virus capture and replication. Induction of a combination of such antibodies may be the key to protection from HIV-1 acquisition.

Original language	English
Article number	110158
Journal	Virology
Volume	597
DOIs	https://doi.org/10.1016/j.virol.2024.110158
State	Published - Sep 2024
Externally published	Yes

Keywords

Broadly neutralizing antibodies
HIV-1 vaccine
Monoclonal antibodies
PBMCs
Primary virus
RV144
RV305
V2 region
Virus capture
qRT-PCR

Access to Document

10.1016/j.virol.2024.110158

Cite this

@article{79261ed94ac84505bce6252a3bd4f217,

title = "Broadly neutralizing antibodies and monoclonal V2 antibodies derived from RV305 inhibit capture and replication of HIV-1",

abstract = "An important approach to stopping the AIDS epidemic is the development of a vaccine that elicits antibodies that block virus capture, the initial interactions of HIV-1 with the target cells, and replication. We utilized a previously developed qRT-PCR-based assay to examine the effects of broadly neutralizing antibodies (bNAbs), plasma from vaccine trials, and monoclonal antibodies (mAbs) on virus capture and replication. A panel of bNAbs inhibited primary HIV-1 replication in PBMCs but not virus capture. Plasma from RV144 and RV305 trial vaccinees demonstrated inhibition of virus capture with the HIV-1 subtype prevalent in Thailand. Several RV305 derived V2-specific mAbs inhibited virus replication. One of these RV305 derived V2-specific mAbs inhibited both virus capture and replication, demonstrating that it is possible to elicit antibodies by vaccination that inhibit virus capture and replication. Induction of a combination of such antibodies may be the key to protection from HIV-1 acquisition.",

keywords = "Broadly neutralizing antibodies, HIV-1 vaccine, Monoclonal antibodies, PBMCs, Primary virus, RV144, RV305, V2 region, Virus capture, qRT-PCR",

author = "Jiae Kim and Zuzana Villar and Ousman Jobe and Supachai Rerks-Ngarm and Punnee Pitisuttithum and Sorachai Nitayaphan and O'Connell, {Robert J.} and Ake, {Julie A.} and Sandhya Vasan and Rao, {Venigalla B.} and Mangala Rao",

note = "Publisher Copyright: {\textcopyright} 2024",

year = "2024",

month = sep,

doi = "10.1016/j.virol.2024.110158",

language = "English",

volume = "597",

journal = "Virology",

issn = "0042-6822",

}

TY - JOUR

T1 - Broadly neutralizing antibodies and monoclonal V2 antibodies derived from RV305 inhibit capture and replication of HIV-1

AU - Kim, Jiae

AU - Villar, Zuzana

AU - Jobe, Ousman

AU - Rerks-Ngarm, Supachai

AU - Pitisuttithum, Punnee

AU - Nitayaphan, Sorachai

AU - O'Connell, Robert J.

AU - Ake, Julie A.

AU - Vasan, Sandhya

AU - Rao, Venigalla B.

AU - Rao, Mangala

PY - 2024/9

Y1 - 2024/9

N2 - An important approach to stopping the AIDS epidemic is the development of a vaccine that elicits antibodies that block virus capture, the initial interactions of HIV-1 with the target cells, and replication. We utilized a previously developed qRT-PCR-based assay to examine the effects of broadly neutralizing antibodies (bNAbs), plasma from vaccine trials, and monoclonal antibodies (mAbs) on virus capture and replication. A panel of bNAbs inhibited primary HIV-1 replication in PBMCs but not virus capture. Plasma from RV144 and RV305 trial vaccinees demonstrated inhibition of virus capture with the HIV-1 subtype prevalent in Thailand. Several RV305 derived V2-specific mAbs inhibited virus replication. One of these RV305 derived V2-specific mAbs inhibited both virus capture and replication, demonstrating that it is possible to elicit antibodies by vaccination that inhibit virus capture and replication. Induction of a combination of such antibodies may be the key to protection from HIV-1 acquisition.

AB - An important approach to stopping the AIDS epidemic is the development of a vaccine that elicits antibodies that block virus capture, the initial interactions of HIV-1 with the target cells, and replication. We utilized a previously developed qRT-PCR-based assay to examine the effects of broadly neutralizing antibodies (bNAbs), plasma from vaccine trials, and monoclonal antibodies (mAbs) on virus capture and replication. A panel of bNAbs inhibited primary HIV-1 replication in PBMCs but not virus capture. Plasma from RV144 and RV305 trial vaccinees demonstrated inhibition of virus capture with the HIV-1 subtype prevalent in Thailand. Several RV305 derived V2-specific mAbs inhibited virus replication. One of these RV305 derived V2-specific mAbs inhibited both virus capture and replication, demonstrating that it is possible to elicit antibodies by vaccination that inhibit virus capture and replication. Induction of a combination of such antibodies may be the key to protection from HIV-1 acquisition.

KW - Broadly neutralizing antibodies

KW - HIV-1 vaccine

KW - Monoclonal antibodies

KW - PBMCs

KW - Primary virus

KW - RV144

KW - RV305

KW - V2 region

KW - Virus capture

KW - qRT-PCR

UR - http://www.scopus.com/inward/record.url?scp=85196824030&partnerID=8YFLogxK

U2 - 10.1016/j.virol.2024.110158

DO - 10.1016/j.virol.2024.110158

M3 - Article

C2 - 38941746

AN - SCOPUS:85196824030

SN - 0042-6822

VL - 597

JO - Virology

JF - Virology

M1 - 110158

ER -

Broadly neutralizing antibodies and monoclonal V2 antibodies derived from RV305 inhibit capture and replication of HIV-1

Abstract

Keywords

Access to Document

Fingerprint

Cite this